Therapeutic conundrum: AIDS therapies may be double-edged swords

David B. Clifford

doi:10.1212/WNL.0b013e3181dd4e31

Therapeutic conundrum: AIDS therapies may be double-edged swords

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1248-1249
Number of pages	2
Journal	Neurology
Volume	74
Issue number	16
DOIs	https://doi.org/10.1212/WNL.0b013e3181dd4e31
State	Published - Apr 2010

Access to Document

10.1212/WNL.0b013e3181dd4e31

Cite this

@article{9fc49cf93e004f468b21eff62e6daf79,

title = "Therapeutic conundrum: AIDS therapies may be double-edged swords",

author = "Clifford, {David B.}",

note = "Funding Information: Dr. Clifford serves/has served on scientific advisory boards for Biogen Idec, Elan Corporation, Roche, Forest Laboratories, Inc., Genentech, Inc., GlaxoSmithKline, Millennium Pharmaceuticals, Inc., Schering-Plough Corp., Bristol-Meyers Squibb, and Genzyme Corporation; received speaker honorarium and funding for travel from GlaxoSmithKline; has received research support from Pfizer Inc., Schering-Plough Corp., Bavarian Nordic, NeurogesX, GlaxoSmithKline, Tibotec Therapeutics, Boehringer Ingelheim, and Gilead Sciences, Inc.; and receives research support from the NIH [ UO1 NS32228 (PI), UO1 AI69495 (PI) , NIMH 22005 CHARTER Project (Site PI), NIDA RO3 DA022137 (Co-I) , NIMH MH058076 (Site PI) , and R21 3857-53187 (PI) ].",

year = "2010",

month = apr,

doi = "10.1212/WNL.0b013e3181dd4e31",

language = "English",

volume = "74",

pages = "1248--1249",

journal = "Neurology",

issn = "0028-3878",

number = "16",

}

TY - JOUR

T1 - Therapeutic conundrum

T2 - AIDS therapies may be double-edged swords

AU - Clifford, David B.

N1 - Funding Information: Dr. Clifford serves/has served on scientific advisory boards for Biogen Idec, Elan Corporation, Roche, Forest Laboratories, Inc., Genentech, Inc., GlaxoSmithKline, Millennium Pharmaceuticals, Inc., Schering-Plough Corp., Bristol-Meyers Squibb, and Genzyme Corporation; received speaker honorarium and funding for travel from GlaxoSmithKline; has received research support from Pfizer Inc., Schering-Plough Corp., Bavarian Nordic, NeurogesX, GlaxoSmithKline, Tibotec Therapeutics, Boehringer Ingelheim, and Gilead Sciences, Inc.; and receives research support from the NIH [ UO1 NS32228 (PI), UO1 AI69495 (PI) , NIMH 22005 CHARTER Project (Site PI), NIDA RO3 DA022137 (Co-I) , NIMH MH058076 (Site PI) , and R21 3857-53187 (PI) ].

PY - 2010/4

Y1 - 2010/4

UR - http://www.scopus.com/inward/record.url?scp=77951494175&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181dd4e31

DO - 10.1212/WNL.0b013e3181dd4e31

M3 - Editorial

C2 - 20338919

AN - SCOPUS:77951494175

SN - 0028-3878

VL - 74

SP - 1248

EP - 1249

JO - Neurology

JF - Neurology

IS - 16

ER -

Therapeutic conundrum: AIDS therapies may be double-edged swords

Access to Document

Other files and links

Cite this